


PLEASE SUPPORT BUDGET AMENDMENT ITEM 303 #5h

Chief Patron: Delegate Rodney Willett

Rx Partnership requests \$100,000 increase in state GF in FY21 & FY22 to support Rx Partnership's generic medication access programs

- Despite Medicaid expansion in 2019, **over 300,000 Virginians are left uninsured.**
- Prices of medications are skyrocketing, making it hard for vulnerable Virginians to afford the prescriptions they need. In 2019, there was an **average price increase of 8.2%** for 629 brand and generic drugs (*GoodRx's 2019 End of the Year Report*).
- Every dollar invested in RxP's programs has **3 times the buying power** compared to a retail pharmacy.
- Based upon the growth and success of our generic program and the depletion of private pilot funding, **Rx Partnership is seeking financial support for our current program needs and to expand program utilization by 20% over the biennium.**



The Commonwealth of Virginia's Return on Investment:

For every \$1 appropriated by the Virginia General Assembly, uninsured patients have received \$132 in prescription retail value through RxP since 2004.



Patient Impact

A typical patient with hypertension, diabetes, high-cholesterol, depression and GERD would take **five** medications. A 90-day prescription of each of these five medications would cost a patient \$92 at Walmart. It costs RxP \$6.74 to provide these five medications to a free clinic patient. **That's a difference of over \$85!**



Questions?

Contact Amy Yarcich at 804.297.3173
or ayarcich@rxpartnership.org

Rx Partnership has worked through our network of 30 clinic partners serving 85 localities across Virginia to provide brand & generic medications to low-income, uninsured Virginians since 2004. Through RxP's innovative and cost-effective programs, RxP secures both donated medications and leverages purchasing power to provide critically needed medications to treat chronic conditions.